Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104490 · ClinicalTrials.gov registry record
Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 79
- Enrollment target
NCT04104490 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 79 participants.
The verdict
NCT04104490 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension. Deidentified human samples will be tested for gut dysbiosis in PAH, circulating bacterial metabolites and markers of inflammation and gut leakiness. The gut microbiome and circulating metabolites, markers of inflammation and gut leakiness of PAH patients and healthy subjects will be compared in deidentified fecal samples and blood.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2015-06-06 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04104490
The ClinicalTrials.gov registry entry for NCT04104490 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04104490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04104490 about?
NCT04104490 is a clinical study titled "Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension". Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension. Deidentified human samples will be tested for gut dysbiosis in PAH, circulating bacterial metabolites and markers of...
What is the current status of trial NCT04104490?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2015-06-06. Estimated completion is 2021-12-31.
Who is sponsoring clinical trial NCT04104490?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.